EXPRESSION OF INTERLEUKIN-10 AND ITS VALUE AS A POTENTIAL MARKER IN ORAL SQUAMOUS CELL CARCINOMA
Ali, M., Omar, T., El Sheikh, S., Swaify, G., Fayad, A. (2018). EXPRESSION OF INTERLEUKIN-10 AND ITS VALUE AS A POTENTIAL MARKER IN ORAL SQUAMOUS CELL CARCINOMA. EKB Journal Management System, 43(1), 11-16. doi: 10.21608/adjalexu.2018.57589
Maggi N. Ali; Taissir A. Omar; Sahar M. El Sheikh; Gamal A. Swaify; Amira I. Fayad. "EXPRESSION OF INTERLEUKIN-10 AND ITS VALUE AS A POTENTIAL MARKER IN ORAL SQUAMOUS CELL CARCINOMA". EKB Journal Management System, 43, 1, 2018, 11-16. doi: 10.21608/adjalexu.2018.57589
Ali, M., Omar, T., El Sheikh, S., Swaify, G., Fayad, A. (2018). 'EXPRESSION OF INTERLEUKIN-10 AND ITS VALUE AS A POTENTIAL MARKER IN ORAL SQUAMOUS CELL CARCINOMA', EKB Journal Management System, 43(1), pp. 11-16. doi: 10.21608/adjalexu.2018.57589
Ali, M., Omar, T., El Sheikh, S., Swaify, G., Fayad, A. EXPRESSION OF INTERLEUKIN-10 AND ITS VALUE AS A POTENTIAL MARKER IN ORAL SQUAMOUS CELL CARCINOMA. EKB Journal Management System, 2018; 43(1): 11-16. doi: 10.21608/adjalexu.2018.57589

EXPRESSION OF INTERLEUKIN-10 AND ITS VALUE AS A POTENTIAL MARKER IN ORAL SQUAMOUS CELL CARCINOMA

Alexandria Dental Journal
Article 3, Volume 43, Issue 1, April 2018, Page 11-16  XML PDF (773.1 K)
Document Type: Original Article
DOI: 10.21608/adjalexu.2018.57589
View on SCiNiTO View on SCiNiTO
Authors
Maggi N. Ali1; Taissir A. Omar2; Sahar M. El Sheikh3; Gamal A. Swaify4; Amira I. Fayad5
1Instructor in Oral Pathology Department, Faculty of Dentistry, Alexandria University.
2Professor in Oral Pathology Department.
3Vice Dean of student`s affairs, Professor in Oral Pathology Department.
4- Professor in Cranio Maxillofacial and Plastic Surgery
5Lecturer in Clinical Pathology Department, Faculty of Medicine
Abstract
INTRODUCTION: Oral squamous cell carcinoma (OSCC) is the commonest malignancy in oral cavity. Dysregulated inflammatory processes could impose a cancer risk. Cytokines are inflammatory mediators that can induce cell proliferation. Interleukin-10 is a pleiotropic cytokine which has a dual role in cancer pathogenesis. It contributes to tumor growth and in other cases to tumor rejection. OBJECTIVES: To evaluate and correlate the expression of IL-10 in different histopathological grades of OSCC, as well as to assess its serum and salivary levels. MATERIALS AND METHODS: Immunohistochemical (IHC) study using the IL-10 antibody was done on 20 surgical specimens and 5 normal mucosal tissues taken from OSCC patients and healthy individuals, respectively. Serum and salivary levels of IL-10 were also measured with a human IL-10 ELISA Kit in both patients and controls. RESULTS: OSCC biopsies showed immunoreactivity to IL-10, while normal tissues were immunonegative. The IHC staining intensity was directly proportional to the grading of OSCC. Conversely, it showed no significant correlation to the disease stage. The difference in the serum and salivary IL-10 levels in patients and controls was not statistically significant. However, there was a significant correlation between IL-10 tissue expression and its serum and salivary levels in OSCC patients. CONCLUSIONS: IL-10 is expressed in OSCC biopsies. Additionally, the levels of IL-10 in tissue, serum and saliva were correlated to each other. This could reflect the same way of regulation of IL-10 in different parts of the body.
Keywords
OSCC; Cytokines; IL-10; Imunohistochemistry; ELISA
References
  1. Sharma P, Saxena S, Aggarwal P. Trends in the epidemiology of oral squamous cell carcinoma in Western UP: an institutional study. Indian J Dent Res. 2010; 21:316- 9.
  2. Singh PK, Ahmad MK, Kumar V, Gupta R, Kohli M, Jain A, et al. Genetic polymorphism of interleukin-10 (-A592C) among oral cancer with squamous cell carcinoma. Arch Oral Biol. 2017; 7:56-70.
  3. de Castro Junior G, dos Santos-Silva AR, Folgueira MAdAK, Toporcov T. Tongue cancer in the young. Curr Opin Oncol. 2016; 28:193-4.
  4. Karin M. Nuclear factor-kB in cancer development and progression. Nature. 2006; 441:431-6.
  5. Aivaliotis IL, Pateras IS, Papaioannou M, Glytsou C, Kontzoglou K, Johnson EO, et al. How do cytokines trigger genomic instability? J Biomed Biotechnol. 2012; 14:1681-5.
  6. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer. 2004; 4:11-22.
  7. Hamzavi M, Tadbir AA, Rezvani G, Ashraf MJ, Fattahi MJ, Khademi B, et al. Tissue expression, serum and salivary levels of IL-10 in patients with head and neck squamous cell carcinoma. Asian Pac J Cancer Prev. 2013; 14:1681-5.
  8. Sakamoto T, Saito H, Tatebe S, Tsujitani S, Ozaki M, Ito H, et al. Interleukin-10 expression significantly correlates with minor CD8+ T cell infiltration and high microvessel density in patients with gastric cancer. Int J Cancer. 2006; 118:1909-14.
  9. Heckel MC, Wolfson A, Slachta CA, Schwarting R, Salgame P, Katsetos CD, et al. Human breast tumor cells express IL-10 and IL-12p40 transcripts and proteins, but do not produce IL-12p70. Cell Immunol. 2011; 266:143-53.
  10. Hatanaka H, Abe Y, Kamiya T, Morino F, Nagata J, Tokunaga T, et al. Clinical implications of interleukin (IL)- 10 induced by non-small-cell lung cancer. Ann Oncol. 2000; 11:815-9.
  11. Chen CJ, Sung WW, Su TC, Chen MK, Wu PR, Yeh KT, et al. High expression of interleukin 10 might predict poor prognosis in early stage oral squamous cell carcinoma patients. Clin Chim Acta. 2013; 415:25-30.
  12. Itakura E, Huang RR, Wen DR, Paul E, Wunsch PH, Cochran AJ. IL-10 expression by primary tumor cells correlates with melanoma progression from radial to vertical growth phase and development of metastatic competence. Mod Pathol. 2011; 24:801-9.
  13. Boulland ML1, Meignin V, Leroy-Viard K, CopieBergman C, Brière J, Touitou R, et al. Human interleukin10 expression in T/natural killer-cell lymphomas: association with anaplastic large cell lymphomas and nasal natural killer-cell lymphomas. The Am J Pathol. 1998; 153:1229-37.
  14. Fujieda S, Sunaga H, Tsuzuki H, Fan GK, Saito H. IL-10 expression is associated with the expression of plateletderived endothelial cell growth factor and prognosis in oral and oropharyngeal carcinoma. Cancer Lett. 1999; 136:1-9.
  15. Chandler SW, Rassekh CH, Rodman SM, Ducatman BS. Immunohistochemical Localization of Interleukin-10 in Human Oral and Pharyngeal Carcinomas. Laryngoscope. 2002; 112:808-15.
  16. Wang S, Sun M, Gu C, Wang X, Chen D, Zhao E, et al. Expression of CD163, interleukin-10, and interferon gamma in oral squamous cell carcinoma: mutual relationships and prognostic implications. Eur J Oral Sci. 2014; 122:202-9.
  17. Gonalves AS, Arantes DAC, Bernardes VF, Jaeger F, Silva JM, Silva TA, et al. Immunosuppressive mediators of oral squamous cell carcinoma in tumour samples and saliva. Hum Immunol. 2015; 76:52-8.
  18. Arantes DAC. Overexpression of immunosuppressive cytokines is associated with poorer clinical stage of oral squamous cell carcinoma. Arch Oral Biol. 2015; 5:1077-89.
  19. Smith DR, Kunkel SL, Burdick MD, Wilke CA, Orringer MB, Whyte RI, et al. Production of interleukin-10 by human bronchogenic carcinoma. Am J Pathol. 1994; 145:18-25.
  20. Alhamarneh O, Agada F, Madden L, Stafford N, Greenman J. Serum IL10 and circulating CD4+ CD25high regulatory T cell numbers as predictors of clinical outcome and survival in patients with head and neck squamous cell carcinoma. Head Neck. 2010; 33:415-23.
  21. Czerninski R, Basile JR, Kartin Gabay T, Laviv A, Barak V. Cytokines and tumor markers in potentially malignant disorders and oral squamous cell carcinoma: a pilot study. Oral Dis. 2014; 20:477-81.
  22. Linkov F, Lisovich A, Yurkovetsky Z, Marrangoni A, Velikokhatnaya L, Nolen B, et al. Early detection of head and neck cancer: development of a novel screening tool using multiplexed immunobead-based biomarker profiling. Cancer Epidemiol Biomarkers Prev. 2007; 16:102-7.
  23. Hoffmann TK, Sonkoly E, Homey B, Scheckenbach K, Gwosdz C, Bas M, et al. Aberrant cytokine expression in serum of patients with adenoid cystic carcinoma and squamous cell carcinoma of the head and neck. Head Neck. 2007; 29:472-8.
  24. De Vita F, Orditura M, Galizia G, Romano C, Infusino S, Auriemma A, et al. Serum interleukin-10 levels in patients with advanced gastrointestinal malignancies. Cancer. 1999; 86:1936-43.
  25. Avradopoulos K, Mehta S, Blackinton D, Wanebo HJ. Interleukin-10 as a possible mediator of immunosuppressive effect in patients with squamous cell carcinoma of the head and neck. Ann Surg Oncol. 1997; 4:184-90.
  26. Fortis C, Foppoli M, Gianotti L, Galli L, Citterio G, Consogno G, et al. Increased interleukin-10 serum levels in patients with solid tumours. Cancer Lett. 1996; 104:1-5.
  27. Gianotti L, Fortis C, Braga M, Gentilini O, Vignali A, Di Carlo V. Radical oncologic surgery affects the circulatory levels of interleukin 10. J Surg Oncol. 1997; 66:244-7.
  28. Gaiolla RD, Domingues MAC, Niero-Melo L, de Oliveira DE. Serum levels of interleukins 6, 10, and 13 before and after treatment of classic Hodgkin lymphoma. Arch Pathol Lab Med. 2011; 135:483-9.
  29. Nelson EL, Wenzel LB, Osann K, Dogan-Ates A, Chantana N, Reina-Patton A, et al. Stress, immunity, and cervical cancer: biobehavioral outcomes of a randomized clinical trial. Clin Cancer Res. 2008; 14:2111-8.
  30. Aziz S, Ahmed SS, Ali A, Khan FA, Zulfiqar G, Iqbal J, et al. Salivary immunosuppressive cytokines IL-10 and IL-13 are significantly elevated in oral squamous cell carcinoma patients. Cancer Invest. 2015; 33:318-28.
  31. Polz-Dacewicz M, Strycharz-Dudziak M, Dworzaski J, Stec A, Kocot J. Salivary and serum IL-10, TNF-α, TGF-β, VEGF levels in oropharyngeal squamous cell carcinoma and correlation with HPV and EBV infections. Infect Agent Cancer. 2016; 11:45.
  32. Szabo YZ, Newton TL, Miller JJ, Lyle KB, FernandezBotran R. Acute stress induces increases in salivary IL-10 levels. Stress. 2016; 19:499-505.
  33. Wozniak KL, Arribas A, Leigh JE, Fidel PL. Inhibitory effects of whole and parotid saliva on immunomodulators. Oral Microbiol Immunol. 2002; 17:100-7.
Statistics
Article View: 268
PDF Download: 405